Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 168303, 6 pages
http://dx.doi.org/10.1155/2012/168303
Research Article

Hepatic Arterial Therapy with Drug-Eluting Beads in the Management of Metastatic Pancreatic Carcinoma to the Liver: A Multi-Institutional Registry

1Division of Surgical Oncology, Department of Surgery, University of Louisville School of Medicine, 315 East Broadway, Room 311, Louisville, KY 40292, USA
2Norton Radiology, Norton Hospital, 301 South Floyd Street, Louisville, Ky 40202, USA
3Baptist Health, Little Rock, AR 23011, USA

Received 28 September 2011; Revised 28 November 2011; Accepted 1 December 2011

Academic Editor: Dirk Arnold

Copyright © 2012 Raffi Kotoyan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar
  2. H. A. Burris III, M. J. Moore, J. Andersen et al., “Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2403–2413, 1997. View at Google Scholar · View at Scopus
  3. M. Tempero, W. Plunkett, V. R. van Haperen et al., “Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma,” Journal of Clinical Oncology, vol. 21, no. 18, pp. 3402–3408, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J. Moore, “Brief communication: a new combination in the treatment of advanced pancreatic cancer,” Seminars in Oncology, vol. 32, supplement 2, pp. S5–S6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Cunningham, I. Chau, D. D. Stocken et al., “Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer,” Journal of Clinical Oncology, vol. 27, no. 33, pp. 5513–5518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Liapi and J. F. H. Geschwind, “Transcatheter and ablative therapeutic approaches for solid malignancies,” Journal of Clinical Oncology, vol. 25, no. 8, pp. 978–986, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Artinyan, R. Nelson, P. Soriano et al., “Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver,” HPB, vol. 10, no. 6, pp. 396–404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. L. Lewis, R. R. Taylor, B. Hall, M. V. Gonzalez, S. L. Willis, and P. W. Stratford, “Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization,” Journal of Vascular and Interventional Radiology, vol. 17, no. 8, pp. 1335–1343, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. L. Lewis, M. V. Gonzalez, A. W. Lloyd et al., “DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization,” Journal of Vascular and Interventional Radiology, vol. 17, no. 2, pp. 335–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. T. Poon, W. K. Tso, R. W. Pang et al., “A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead,” Clinical Gastroenterology and Hepatology, vol. 5, no. 9, pp. 1100–1108, 2007. View at Google Scholar · View at Scopus
  11. J. Lammer, K. Malagari, T. Vogl et al., “Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study,” CardioVascular and Interventional Radiology, vol. 33, no. 1, pp. 41–52, 2010. View at Publisher · View at Google Scholar
  12. M. N. Levine and J. A. Julian, “Registries that show efficacy: good, but not good enough,” Journal of Clinical Oncology, vol. 26, no. 33, pp. 5316–5319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. R. C. Martin, K. Robbins, D. Tomalty et al., “Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report,” World Journal of Surgical Oncology, vol. 7, article 80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. C. Martin, J. Joshi, K. Robbins et al., “Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study,” Annals of Surgical Oncology, vol. 18, no. 1, pp. 192–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Lencioni and J. M. Llovet, “Modified recist (mRECIST) assessment for hepatocellular carcinoma,” Seminars in Liver Disease, vol. 30, no. 1, pp. 52–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Joshi, K. Robbins, V. Válek et al., “Transarterial chemoembolization with drug-eluting beads loaded with doxorubicin for the treatment of metastatic breast cancer to the liver: results from a multiinstitutional registry,” Journal of Interventional Oncology, vol. 3, no. 2, pp. 145–152, 2010. View at Google Scholar
  17. R. E. Brown, K. M. Gibler, T. Metzger et al., “Imaged guided transarterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for hepatic metastases from melanoma: early outcomes from a multi-institutional registry,” American Surgeon, vol. 77, no. 1, pp. 93–98, 2011. View at Google Scholar · View at Scopus
  18. R. C. Martin, J. Howard, D. Tomalty et al., “Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry,” CardioVascular and Interventional Radiology, vol. 33, no. 5, pp. 960–966, 2010. View at Publisher · View at Google Scholar
  19. T. de Baere, F. Deschamps, C. Teriitheau et al., “Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results,” Journal of Vascular and Interventional Radiology, vol. 19, no. 6, pp. 855–861, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. B. Brown, C. F. Gonsalves, C. J. Yeo, A. K. Witkiewicz, and B. I. Carr, “One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin,” Oncology Reports, vol. 24, no. 3, pp. 767–769, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. E. S. Casper, M. R. Green, D. P. Kelsen et al., “Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas,” Investigational New Drugs, vol. 12, no. 1, pp. 29–34, 1994. View at Publisher · View at Google Scholar
  22. T. Okusaka, A. Funakoshi, J. Furuse et al., “A late phase II study of S-1 for metastatic pancreatic cancer,” Cancer Chemotherapy and Pharmacology, vol. 61, no. 4, pp. 615–621, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. M. Chue, “Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope,” Gastrointestinal Cancer Research, vol. 3, no. 5, pp. 208–211, 2009. View at Google Scholar · View at Scopus